MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-? Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting
Medical Marijuana Program Connection
FEBRUARY 28, 2023
BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc.® ® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the. Read More
Let's personalize your content